Figures & data
Table 1 Baseline characteristics of patients
Figure 1 Patients with normalized blood pressure (BP) (A) and responders (B) to candesartan cilexetil (CC) (8–16 mg) at week 4 and week 8. Patients were considered as normalized according to two systolic (S) and diastolic (D) BP targets: SBP/DBP <140/90 mmHg, and SBP/DBP <150/90 mmHg. Patients were considered as responders if they achieved SBP <140 mmHg or a reduction of 20 mmHg on the SBP compared with the baseline value and DBP <90 mmHg or a reduction of 10 mmHg on the DBP compared with the baseline value. Two BP targets were evaluated: SBP/DBP <140/90 mmHg, and SBP/DBP <150/90 mmHg. Week 4, n=2951 and week 8, n=2847. At week 8, 1659 patients received CC 8/8 mg and 1187 patients received CC 8/16 mg.
Table 2 Mean blood pressure (BP) values (mean ± SD) at baseline, and after 4 weeks and 8 weeks of candesartan cilexetil (CC)
Figure 2 Effect of candesartan cilexetil on systolic blood pressure according to previous antihypertensive treatment. Values are presented as confidence interval 95%.
Table 3 Influence of age, sex, and diabetes on the systolic and diastolic blood pressure (SBP, DBP) changes (mean ± SD) of patients treated with candesartan cilexetil (CC)